Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 7/20 | 0.77 |
| ▸ | MAP4K4 | O95819 | 7/20 | 0.77 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.77 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.77 |
| ▸ | CSNK1A1 | P48729 | 6/20 | 0.77 |
| ▸ | GSK3B | P49841 | 6/20 | 0.77 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.77 |
| ▸ | CSNK1G2 | P78368 | 5/20 | 0.77 |
| ▸ | CSNK1G3 | Q9Y6M4 | 5/20 | 0.77 |
| ▸ | PRKD2 | Q9BZL6 | 5/20 | 0.77 |
| ▸ | CSNK1G1 | Q9HCP0 | 4/20 | 0.77 |
| ▸ | MINK1 | Q8N4C8 | 4/20 | 0.77 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.77 |
| ▸ | GSK3A | P49840 | 3/20 | 0.77 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.77 |
| ▸ | CDK2 | P24941 | 1/20 | 0.77 |
| ▸ | CLK2 | P49760 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477389 | 0.93 | MAPK8 (0.66) | PRKD3MAP4K4MAPK8MAPK9CSNK1A1 | |
| SCHEMBL3816982 | 0.92 | MAP4K4 (0.79) | PRKD3MAP4K4MAPK8MAPK9CSNK1A1 | |
| SCHEMBL12042802 | 0.91 | PRKD3 (0.64) | PRKD3MAP4K4MAPK8MAPK9CSNK1A1 | |
| SCHEMBL2746232 | 0.90 | PRKD3 (0.62) | PRKD3MAP4K4MAPK8MAPK9CSNK1A1 | |
| SCHEMBL3813008 | 0.89 | MAPK9 (0.71) | PRKD3MAP4K4MAPK8MAPK9CSNK1A1 | |
| SCHEMBL3817051 | 0.88 | CDK2 (0.59) | PRKD3MAP4K4MAPK8MAPK9CSNK1A1 | |
| SCHEMBL3808587 | 0.87 | PRKD3 (1.00) | PRKD3MAP4K4MAPK8MAPK9CSNK1A1 | |
| SCHEMBL3813109 | 0.86 | MAPK8 (0.75) | PRKD3MAP4K4MAPK8MAPK9CSNK1A1 | |
| Hydrochloric Acid SCHEMBL2746187 | 0.85 | MAPK8 (0.74) | PRKD3MAP4K4MAPK8MAPK9CSNK1A1 | |
| SCHEMBL2746062 | 0.83 | PRKD3 (0.55) | PRKD3MAP4K4MAPK8MAPK9CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK8, MAPK7 | PRKD3 541/4885MAP4K4 44/4885MAPK8 2/4885 |
| US-20070281955-A1 | RAF inhibitors and their uses | BRAF, RAF1, ARAF | PRKD3 472/4885MAP4K4 79/4885MAPK8 301/4885 |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | BRAF, RAF1, ARAF | PRKD3 469/4885MAP4K4 72/4885MAPK8 298/4885 |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK7, MAPK8 | PRKD3 507/4885MAP4K4 43/4885MAPK8 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.